{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:21:13Z","timestamp":1790108473492,"version":"4.0.1"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Whether targeted therapies for non-small cell lung cancer (NSCLC) share mechanism-driven class toxicities or mainly exhibit drug-specific risks remains unclear in real-world practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We analyzed reports from the U.S. FDA Adverse Event Reporting System (FAERS, 2004\u20132025) for 14 Food and Drug Administration (FDA)-approved agents across five classes: EGFR, ALK, ROS1, RET tyrosine kinase inhibitors (TKIs), and a KRAS G12C inhibitor. Adverse events (AEs) were standardized to MedDRA v27.0 preferred terms (PTs). Primary PT-level safety signals were defined based on concordance across four disproportionality methods: proportional reporting ratio (PRR; PRR \u2265 2, x\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0\u2265\u00a04, and \u22653 reports), reporting odds ratio (ROR; lower 95% confidence interval bound ROR\n                      <jats:sub>025<\/jats:sub>\n                      \u00a0&gt;\u00a01), Bayesian confidence propagation neural network (BCPNN; IC\n                      <jats:sub>025<\/jats:sub>\n                      &gt;\u00a00), and the multi-item gamma Poisson shrinker (MGPS; EB05\u00a0\u2265\u00a02). Cross-drug structure was evaluated via a Jaccard-based similarity network.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 34\u00a0948 individuals, per-drug signal counts ranged from 3 to 113. EGFR-TKIs were enriched for mucocutaneous and gastrointestinal events; ALK-TKIs for metabolic and laboratory abnormalities and selected cardiac findings; and RET-TKIs for hepatotoxicity and hypertension. Osimertinib showed prominent electrocardiographic signals (e.g., QT prolongation); lorlatinib exhibited a distinctive dyslipidemia signature. Brigatinib and crizotinib aligned with creatine kinase elevation and visual effects, respectively. No single PT occurred across all 14 drugs. Recurrent cross-class PTs included increased blood pressure, QT prolongation, dry skin, and edema. The similarity network revealed tight within-class modules (EGFR, ALK), a binary RET pair, and peripheral placement of repotrectinib and adagrasib, indicating limited overlap of their AE profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This first NSCLC-focused FAERS comparison integrating four-method signal detection with network analysis delineates reproducible class effects superimposed by drug-specific toxicities. Findings support tailored monitoring (e.g., dermatologic care for EGFR-TKIs; ECG\/electrolytes for osimertinib; lipid\/CK surveillance for ALK-TKIs; blood pressure\/liver testing for RET-TKIs) to inform risk-aware first-line decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000004704","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:01:29Z","timestamp":1769011289000},"page":"9520-9534","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["From class effects to specificity FAERS evidence and network mapping of adverse events in NSCLC targeted therapy"],"prefix":"10.1097","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-7966","authenticated-orcid":false,"given":"Jinsheng","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China"},{"name":"The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China"},{"name":"The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China"},{"name":"The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5692-1217","authenticated-orcid":false,"given":"Qijin","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China"},{"name":"The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"R1-20260424","first-page":"229\u201363","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260424","first-page":"12\u201349","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R3-20260424","first-page":"55613\u201321","article-title":"Positive expression of Y-box binding protein 1 and prognosis in non-small cell lung cancer: a meta-analysis","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"R4-20260424","doi-asserted-by":"crossref","first-page":"677\u201378","DOI":"10.1038\/s41571-022-00676-4","article-title":"The KRYSTAL-1 study of adagrasib - a new trial for KRAS(G12C)-mutated non-small-cell lung cancer","volume":"19","author":"Murciano-Goroff","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R5-20260424","doi-asserted-by":"crossref","first-page":"615\u201326","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"R6-20260424","doi-asserted-by":"crossref","first-page":"813\u201324","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20260424","doi-asserted-by":"crossref","first-page":"1168\u201378","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann Oncol"},{"key":"R8-20260424","doi-asserted-by":"crossref","first-page":"354\u201366","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R9-20260424","doi-asserted-by":"crossref","first-page":"3400\u201309","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced Alk-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"R10-20260424","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"R11-20260424","doi-asserted-by":"crossref","first-page":"2129\u201339","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"R12-20260424","doi-asserted-by":"crossref","first-page":"947\u201357","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"R13-20260424","doi-asserted-by":"crossref","first-page":"803\u201322","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"R14-20260424","first-page":"367:l5460","article-title":"Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis","author":"Zhao","year":"2019","journal-title":"BMJ"},{"key":"R15-20260424","doi-asserted-by":"crossref","first-page":"633\u201343","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from egfr tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R16-20260424","doi-asserted-by":"crossref","first-page":"63\u201366","DOI":"10.1016\/j.thromres.2021.12.019","article-title":"Osimertinib-related venous thromboembolism in non small lung cancer","volume":"210","author":"Petrelli","year":"2022","journal-title":"Thromb Res"},{"key":"R17-20260424","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/JTO.0b013e3182381564","article-title":"Pneumatosis cystoides intestinalis after gefitinib therapy for pulmonary adenocarcinoma","volume":"7","author":"Iwasaku","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R18-20260424","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-2407-12-87","article-title":"Pneumatosis intestinalis and portal venous gas secondary to gefitinib therapy for lung adenocarcinoma","volume":"12","author":"Lee","year":"2012","journal-title":"BMC Cancer"},{"key":"R19-20260424","doi-asserted-by":"crossref","first-page":"174\u201379","DOI":"10.1016\/j.lungcan.2010.01.018","article-title":"Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis","volume":"70","author":"Olmez","year":"2010","journal-title":"Lung Cancer"},{"key":"R20-20260424","doi-asserted-by":"crossref","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","article-title":"Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"6","author":"Omar","year":"2021","journal-title":"ESMO Open"},{"key":"R21-20260424","first-page":"79","article-title":"Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer","volume":"10","author":"Zaborowska-Szmit","year":"2024","journal-title":"Cardiooncology"},{"key":"R22-20260424","doi-asserted-by":"crossref","first-page":"996\u20131003","DOI":"10.1159\/000539426","article-title":"Relationship between anaplastic lymphoma kinase inhibitors and epileptic seizure disorder: a post-marketing surveillance study","volume":"102","author":"Noguchi","year":"2024","journal-title":"Oncology"},{"key":"R23-20260424","doi-asserted-by":"crossref","first-page":"101332","DOI":"10.1016\/j.xcrm.2023.101332","article-title":"Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers","volume":"4","author":"Nardo","year":"2023","journal-title":"Cell Rep Med"},{"key":"R24-20260424","doi-asserted-by":"crossref","first-page":"1418469","DOI":"10.3389\/fphar.2024.1418469","article-title":"A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system","volume":"15","author":"Wu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R25-20260424","doi-asserted-by":"crossref","first-page":"1112\u201315","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"R26-20260424","doi-asserted-by":"crossref","first-page":"107966","DOI":"10.1016\/j.lungcan.2024.107966","article-title":"Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: a real-world pharmacovigilance study","volume":"196","author":"Chen","year":"2024","journal-title":"Lung Cancer"},{"key":"R27-20260424","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","year":"2025","journal-title":"Prem J Sci"},{"key":"R28-20260424","doi-asserted-by":"crossref","first-page":"1\u20136","DOI":"10.1007\/s43441-022-00393-1","article-title":"MedDRA labeling groupings to improve safety communication in product labels","volume":"57","author":"Grosse-Michaelis","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"R29-20260424","doi-asserted-by":"crossref","first-page":"483\u201386","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R30-20260424","first-page":"3\u201310","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R31-20260424","doi-asserted-by":"crossref","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"R32-20260424","first-page":"293\u2013303","article-title":"Identification of substandard medicines via disproportionality analysis of individual case safety reports","volume":"40","author":"ZA","year":"2017","journal-title":"Drug Saf"},{"key":"R33-20260424","doi-asserted-by":"crossref","first-page":"1099\u2013104","DOI":"10.1592\/phco.24.13.1099.38090","article-title":"Pharmacovigilance in the 21st century: new systematic tools for an old problem","volume":"24","author":"Szarfman","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R34-20260424","doi-asserted-by":"crossref","first-page":"2494781","DOI":"10.1080\/10717544.2025.2494781","article-title":"Biomaterial-based drug delivery: evaluating the safety profiles of liposomal Vyxeos","volume":"32","author":"Liu","year":"2025","journal-title":"Drug Deliv"},{"key":"R35-20260424","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7274","article-title":"EPR25-131: hematologic adverse effects profile of immune checkpoint inhibitors: a real-world pharmacovigilance study using FAERS database","volume":"23","author":"Tariq","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"R36-20260424","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12911-023-02133-3","article-title":"Analysis and identification of drug similarity through drug side effects and indications data","volume":"23","author":"Torab-Miandoab","year":"2023","journal-title":"BMC Med Inform Decis Mak"},{"key":"R37-20260424","doi-asserted-by":"crossref","first-page":"e0311614","DOI":"10.1371\/journal.pone.0311614","article-title":"How strong is strong? The challenge of interpreting network edge weights","volume":"19","author":"Neal","year":"2024","journal-title":"PLoS One"},{"key":"R38-20260424","first-page":"6483\u201388","article-title":"Extracting the multiscale backbone of complex weighted networks","volume":"106","author":"Serrano","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R39-20260424","doi-asserted-by":"crossref","first-page":"e0322298","DOI":"10.1371\/journal.pone.0322298","article-title":"Exploring weighted network backbone extraction: a comparative analysis of structural techniques","volume":"20","author":"Yassin","year":"2025","journal-title":"PLoS One"},{"key":"R40-20260424","doi-asserted-by":"crossref","first-page":"768\u201378","DOI":"10.1016\/j.jtho.2022.02.004","article-title":"Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001","volume":"17","author":"McCoach","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R41-20260424","doi-asserted-by":"crossref","first-page":"674\u201378","DOI":"10.1177\/10781552241304000","article-title":"Cytomegalovirus viremia and hepatitis B reactivation in patient with RET fusion-positive non-small cell lung cancer treated with pralsetinib","volume":"31","author":"Lehman","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"R42-20260424","doi-asserted-by":"crossref","first-page":"629\u201340","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"R43-20260424","doi-asserted-by":"crossref","first-page":"113\u201325","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"R44-20260424","doi-asserted-by":"crossref","first-page":"108629","DOI":"10.1016\/j.lungcan.2025.108629","article-title":"Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis","volume":"205","author":"Gawli","year":"2025","journal-title":"Lung Cancer"},{"key":"R45-20260424","doi-asserted-by":"crossref","first-page":"1625\u201333","DOI":"10.1097\/JTO.0000000000000318","article-title":"Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer","volume":"9","author":"Blackhall","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R46-20260424","doi-asserted-by":"crossref","first-page":"2167\u201377","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"R47-20260424","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40360-025-00859-6","article-title":"Adverse event profile of crizotinib in real-world from the FAERS database: a 12-year pharmacovigilance study","volume":"26","author":"Zhang","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"R48-20260424","doi-asserted-by":"crossref","first-page":"107535","DOI":"10.1016\/j.lungcan.2024.107535","article-title":"A pragmatic guide for management of adverse events associated with lorlatinib","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"key":"R49-20260424","doi-asserted-by":"crossref","first-page":"829\u201338","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"R50-20260424","doi-asserted-by":"crossref","first-page":"917\u201329","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"R51-20260424","doi-asserted-by":"crossref","first-page":"2091\u2013108","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-Positive NSCLC: final Results of Phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R52-20260424","doi-asserted-by":"crossref","first-page":"1491167","DOI":"10.3389\/fonc.2024.1491167","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib","volume":"14","author":"Yin","year":"2024","journal-title":"Front Oncol"},{"key":"R53-20260424","doi-asserted-by":"crossref","first-page":"1305\u201314","DOI":"10.1007\/s11096-025-01917-z","article-title":"Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system database","volume":"47","author":"Shi","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"R54-20260424","doi-asserted-by":"crossref","first-page":"118\u201331","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"key":"R55-20260424","doi-asserted-by":"crossref","first-page":"120\u201331","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation","volume":"387","author":"Janne","year":"2022","journal-title":"N Engl J Med"},{"key":"R56-20260424","doi-asserted-by":"crossref","first-page":"1349636","DOI":"10.3389\/fimmu.2024.1349636","article-title":"Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data","volume":"15","author":"Ding","year":"2024","journal-title":"Front Immunol"},{"key":"R57-20260424","doi-asserted-by":"crossref","first-page":"1040\u201361","DOI":"10.1161\/CIRCRESAHA.121.318051","article-title":"Hypertension and prohypertensive antineoplastic therapies in cancer patients","volume":"128","author":"van Dorst","year":"2021","journal-title":"Circ Res"},{"key":"R58-20260424","doi-asserted-by":"crossref","first-page":"110\u201319","DOI":"10.1016\/j.matbio.2009.01.002","article-title":"Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress","volume":"28","author":"Isenberg","year":"2009","journal-title":"Matrix Biol"},{"key":"R59-20260424","doi-asserted-by":"crossref","first-page":"26069\u201380","DOI":"10.1074\/jbc.M605040200","article-title":"CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1","volume":"281","author":"Isenberg","year":"2006","journal-title":"J Biol Chem"},{"key":"R60-20260424","doi-asserted-by":"crossref","first-page":"758010","DOI":"10.3389\/fcvm.2021.758010","article-title":"Tyrosine kinase inhibitors-induced arrhythmias: from molecular mechanisms, pharmacokinetics to therapeutic strategies","volume":"8","author":"Cheng","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R61-20260424","doi-asserted-by":"crossref","first-page":"1172036","DOI":"10.3389\/fonc.2023.1172036","article-title":"The association between tyrosine kinase inhibitors and fatal arrhythmia in patients with non-small cell lung cancer in Taiwan","volume":"13","author":"Chang","year":"2023","journal-title":"Front Oncol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000004704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:48:14Z","timestamp":1786038494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000004704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000004704","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"2025-10-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}